Clinical Trial Update: A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. [Phase 2]

View source ↗

Summary

Phase II trial evaluating dendritic cells loaded with autologous tumor homogenate as adjuvant vaccination in resected stage IV rare cancers; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Neuroendocrine Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• Dendritic cell vaccine loaded with autologous tumor homogenate (dendritic cell vaccine loaded with autologous tumor homogenate)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Head Neck Tumors, Neuroendocrine Tumors | Phase 2 | Status: RECRUITING